Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7477.091 | 1.1492 | 1.2575 | 1.1485 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7477.091 | 1.2278 | 1.3913 | 1.1485 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7477.091 | 0.7329 | 0.5260 | 1.1485 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7477.091 | 0.0011 | -0.9946 | 1.1485 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7477.091 | 0.0011 | -0.9946 | 1.1485 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 10380.092 | 0.9899 | 0.9864 | 1.4888 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 10380.092 | 1.0357 | 1.0477 | 1.4888 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 10380.092 | 1.0234 | 1.0313 | 1.4888 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 10380.092 | 1.0571 | 1.0760 | 1.4888 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 10380.092 | 0.9503 | 0.9327 | 1.4888 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 10380.092 | 1.0639 | 1.0850 | 1.4888 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 10380.092 | 0.6330 | 0.4711 | 1.4888 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 10380.092 | 0.0129 | -0.8924 | 1.4888 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 10380.092 | 0.0059 | -0.9366 | 1.4888 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7482.091 | 0.9085 | 0.9034 | 1.9368 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7482.091 | 0.8866 | 0.8795 | 1.9368 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7482.091 | 0.9066 | 0.9013 | 1.9368 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7482.091 | 1.0774 | 1.0785 | 1.9368 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7482.091 | 1.0635 | 1.0646 | 1.9368 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7482.091 | 1.1250 | 1.1254 | 1.9368 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7482.091 | 0.5500 | 0.4688 | 1.9368 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7482.091 | 0.0085 | -0.8293 | 1.9368 | |
| MB 157 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7482.091 | 0.0018 | -0.9235 | 1.9368 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7483.091 | 0.9242 | 0.9489 | 3.0465 | |
| MCF 10A | NM | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7483.091 | 0.9917 | 0.9945 | 3.0465 |